Chlorproguanil/dapsone

Chlorproguanil/dapsone (sold commercially as Lapdap) was a fixed dose antimalarial combination containing chlorproguanil and dapsone,^[1] which act synergystically against malaria. The drug was withdrawn in 2008 following increasing evidence of toxicity in the form of haemolysis occurring in patients with G6PD deficiency.^[2]

References

^ Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". Lancet Infect Dis. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.
^ Luzzatto, L. (2010). "The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics". The Lancet. 376 (9742): 739–741. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264.

This antiinfective drug article is a stub. You can help Wikipedia by expanding it.

[pmid12614733-1] Lang T, Greenwood B (March 2003). "The development of Lapdap, an affordable new treatment for malaria". Lancet Infect Dis. 3 (3): 162–8. doi:10.1016/S1473-3099(03)00547-4. PMID 12614733.

[pmid20599264-2] Luzzatto, L. (2010). "The rise and fall of the antimalarial Lapdap: A lesson in pharmacogenetics". The Lancet. 376 (9742): 739–741. doi:10.1016/S0140-6736(10)60396-0. PMID 20599264.

[1]

[2]